The AirDuo Digihaler may help you

Review quality of inhalations and detect missed doses2*†

AirDuo Digihaler

Indicated for the treatment of asthma in patients 12 years of age and older. AirDuo Digihaler is only for patients uncontrolled on an inhaled corticosteroid (ICS) or whose disease severity clearly warrants an ICS/Long-acting beta2-agonist (LABA).

Limitation of Use: AirDuo Digihaler is not indicated for the relief of acute bronchospasm.

Contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures. Contraindicated in patients with known severe hypersensitivity to milk proteins or any ingredients of AirDuo Digihaler.

Please see additional Important Safety Information in the scroll below.

*As measured by inspiratory flow.

†Inhaler use is recorded as an event when a patient opens the cap or inhales.

AirDuo Digihaler

See the Data

AirDuo Digihaler

  • Dosing
  • Features
  • Efficacy
  • Adverse Events

AirDuo Digihaler has the lowest approved dose of fluticasone propionate and salmeterol at each strength2,10

  AirDuo Digihaler   Advair Diskus®
Dosage Fluticasone Propionate Salmeterol   Fluticasone Propionate Salmeterol
Low 55 mcg 14 mcg   100 mcg 50 mcg
Medium 113 mcg 14 mcg   250 mcg 50 mcg
High 232 mcg 14 mcg   500 mcg 50 mcg

Advair Diskus® is a registered trademark of the GSK group of companies

AirDuo Digihaler should be given2:

  • As 1 inhalation twice daily about 12 hours apart
  • By oral inhalation only

Table is intended to show differences in dosing only and should not be construed to imply safety or efficacy similarities or differences

AirDuo Digihaler vs nondigital counterpart

Features AirDuo® Digihaler® AirDuo RespiClick®
Efficacy and safety2 Digihaler inhalers and their nondigital counterparts share the same efficacy and safety profile*
Tracks and categorizes quality of inhalations2    
Measures inspiratory flow rates2    
Tracks how often the inhaler is used2,4,5    
Captures patterns of maintenance inhaler use and missed doses2,4,5    
Connects to a companion mobile app for viewing inhaler use data2    

Inhaler use is recorded as an event when
a cap is opened or a patient inhales.

* The Digihaler products were approved based on the safety and efficacy data from their nondigital counterparts.

Product characteristics listed are not all-inclusive and cannot be used to infer product efficacy or safety

Connection to the app is required for transmission of data, but is not required for delivery of the medicine from the inhaler.

The safety of AirDuo Digihaler has been established from adequate and well-controlled studies of fluticasone propionate and salmeterol MDPI. There is no evidence that the use of the Digihaler app leads to improved clinical outcomes, including safety and effectiveness.

Improvements in lung function in clinical trials2

Fluticasone propionate MDPI demonstrated significantly greater FEV1 improvement vs placebo across all dosage strengths.

Trial 1: Mean change from baseline in trough FEV1 at each visit by treatment group (FAS)

AirDuo Digihaler efficacy chart

Trial 1 Design: This randomized, double-blind, placebo-controlled, 12-week, global efficacy and safety trial compared fluticasone propionate and salmeterol MDPI 55/14 mcg and 113/14 mcg (1 inhalation twice daily) and placebo in adolescent and adult patients with persistent symptomatic asthma despite low-dose or mid-dose ICS or ICS/LABA therapy. Additional arms in this study received fluticasone propionate MDPI 55 mcg and 113 mcg (1 inhalation twice daily).

Fluticasone propionate MDPI demonstrated significantly greater FEV1 improvement vs placebo across all dosage strengths.

Trial 2: Mean change from baseline in trough FEV1 at each visit by treatment group (FAS)

AirDuo Digihaler efficacy chart 2

Trial 2 Design: This randomized, double-blind, placebo-controlled, 12-week, global efficacy and safety trial compared fluticasone propionate and salmeterol MDPI 113/14 mcg and 232/14 mcg (1 inhalation twice daily) and placebo in adolescent and adult patients with persistent symptomatic asthma despite ICS or ICS/LABA therapy. Additional arms in this study received fluticasone propionate MDPI 113 mcg and 232 mcg (1 inhalation twice daily).

Abbreviations: FAS=full analysis set; FEV1=forced expiratory volume in 1 second; ICS=inhaled corticosteroid; LABA=long-
acting beta2-agonist; MDPI=multidose dry powder inhaler

Early onset of action and sustained efficacy in a clinical trials program2

Fluticasone propionate and salmeterol MDPI demonstrated improvement in lung function within 15 minutes of the first dose across all dosage strengths. Maximum improvement in FEV1 generally occurred within 3 hours for fluticasone propionate/salmeterol MDPI 55/14 mcg and within 6 hours for fluticasone propionate/salmeterol MDPI 113/14 mcg.

Trial 1: Serial spirometry—Mean change from baseline in FEV1 at Day 1 by time point and treatment group (FAS; serial spirometry subset)

AirDuo Digihaler efficacy chart 3

Trials 1 and 2: The primary endpoints for these trials were the changes from baseline in trough FEV1 at week 12 for all patients and standardized baseline-adjusted FEV1 AUEC0-12h at week 12 analyzed for a subset of 312 patients who performed post dose serial spirometry.

Fluticasone propionate and salmeterol MDPI demonstrated improvement in lung function within 15 minutes of the first dose across all dosage strengths. Maximum improvement in FEV1 generally occurred within 3 hours for both fluticasone propionate/salmeterol MDPI dose groups.

Trial 2: Serial spirometry—Mean change from baseline FEV1 at Day 1 by time point and treatment group (FAS; serial spirometry subset)

AirDuo Digihaler efficacy chart 4

Trials 1 and 2: The primary endpoints for these trials were the changes from baseline in trough FEV1 at week 12 for all patients and standardized baseline-adjusted FEV1 AUEC0-12h at week 12 analyzed for a subset of 312 patients who performed post dose serial spirometry.

Abbreviation: AUEC0-12h=area under effect-time curve 0-12 hours

Safety profile2

The safety of fluticasone propionate and salmeterol MDPI was evaluated in patients with
asthma who were previously treated with an ICS.

Adverse reactions with ≥3% incidence with fluticasone propionate and salmeterol MDPI
were more common than placebo in subjects with asthma in trials 1 and 2

  Flucticasone propionate and salmeterol MDPI  
Adverse Reaction 55/14 mcg (n=128)
%		 113/14 mcg (n=269)
%		 232/14 mcg (n=145)
%		 Placebo (n=273)
%
NasopharyngitisNasophar-
yngitis		 8.6 4.8 6.9 4.4
Oral candidiasis* 1.6 2.2 3.4 0.7
Back pain 3.1 0.7 0.0 1.8
Headache 5.5 4.8 2.8 4.4
Cough 2.3 3.7 0.7 2.6

*Oral candidiasis includes oropharyngeal candidiasis, oral fungal infection, and oropharyngitis fungal.

In a long-term, open-labeled safety study, the types of adverse reactions were similar to those reported above in the placebo-controlled studies. The 26-week safety study included 674 patients previously treated with ICS who were treated twice daily with fluticasone propionate MDPI 113 mcg or 232 mcg; fluticasone propionate/salmeterol MDPI 113/14 mcg or 232/14 mcg; fluticasone propionate inhalation aerosol 110 mcg or 220 mcg; fluticasone propionate and salmeterol inhalation powder (250/50 mcg), or fluticasone propionate and salmeterol inhalation powder (500/50 mcg), the types of adverse reactions were similar to those reported above in placebo-controlled study.

ADDITIONAL RESOURCES

Help patients get started with
the AirDuo Digihaler

Make sure they pair the inhaler to the app to get the most out of
the Digihaler system.

Find out how
 
 
 
 
​​
Important Safety Information:

AIRDUO® DIGIHALER® (fluticasone propionate and salmeterol) AND ARMONAIR® DIGIHALER® (fluticasone propionate)

  • Contraindications: ArmonAir Digihaler and AirDuo Digihaler are contraindicated in:
    • Primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures
    • Patients with known severe hypersensitivity to milk proteins or any ingredients of ArmonAir Digihaler or AirDuo Digihaler
  • Serious Asthma-Related Events – Hospitalizations, Intubations, Death: Use of a LABA as monotherapy (without an ICS) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinical trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with ICS (such as AirDuo Digihaler), data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone
  • Deterioration of Disease and Acute Episodes: AirDuo Digihaler should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma. ArmonAir Digihaler and AirDuo Digihaler are not indicated for the relief of acute bronchospasm. An inhaled, short-acting beta2-agonist, not ArmonAir Digihaler or AirDuo Digihaler, should be used to relieve acute symptoms such as shortness of breath
  • Avoid Excessive Use and Avoid Use with Other Long acting Beta2-Agonists: AirDuo Digihaler should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

    Patients using AirDuo Digihaler should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason

  • Oropharyngeal Candidiasis has occurred in patients treated with ArmonAir Digihaler or AirDuo Digihaler. Advise patients to rinse the mouth with water without swallowing following inhalation
  • Immunosuppression and Risks of Infections: Patients who use corticosteroids, such as found in AirDuo Digihaler and ArmonAir Digihaler are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Use with caution in patients with the above because of the potential for worsening of these infections
  • Transferring Patients from Systemic Corticosteroid Therapy: Particular care is needed for patients who have been transferred from systemically active corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available ICS. Taper patients slowly from systemic corticosteroids if transferring to ArmonAir Digihaler or AirDuo Digihaler
  • Hypercorticism and Adrenal Suppression may occur with high doses of ICS, including fluticasone propionate, or at the recommended dose in susceptible individuals. If such changes occur, discontinue ArmonAir Digihaler or AirDuo Digihaler slowly
  • Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors: The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, ketoconazole) with ArmonAir Digihaler or AirDuo Digihaler is not recommended because increased systemic corticosteroid adverse effects may occur; increased cardiovascular adverse effects may also occur with AirDuo Digihaler
  • Paradoxical Bronchospasm and Upper Airway Symptoms: Paradoxical bronchospasm may occur. If bronchospasm occurs treat immediately with an inhaled, short-acting bronchodilator discontinue AirDuo Digihaler or ArmonAir Digihaler and institute alternative therapy
  • Hypersensitivity Reactions, Including Anaphylaxis: Immediate hypersensitivity reactions (e.g., urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, may occur after administration of ArmonAir Digihaler or AirDuo Digihaler. Discontinue ArmonAir Digihaler or AirDuo Digihaler if such reactions occur
  • Cardiovascular and Central Nervous System Effects: The salmeterol component of AirDuo Digihaler, can be associated with excessive beta-adrenergic stimulation which could present as the following symptoms: seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Use with caution in patients with cardiac arrhythmias, hypertension, coronary insufficiency. Drug may need to be discontinued in certain patients.
  • Reduction in Bone Mineral Density (BMD): Decreases in BMD have been observed with long-term administration of products containing ICS. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care when using ArmonAir Digihaler or AirDuo Digihaler
  • Effect on Growth: ICS may cause a reduction in growth velocity, Patients should be maintained on the lowest dose of inhaled corticosteroid that effectively controls their asthma. Monitor growth of pediatric patients receiving ArmonAir Digihaler and AirDuo Digihaler.
  • Glaucoma and Cataracts: Long-term use of ICS, including fluticasone propionate, a component of ArmonAir Digihaler and AirDuo Digihaler, may increase the risk for cataracts or glaucoma. Regular eye exams should be considered
  • Eosinophilic Conditions and Churg-Strauss Syndrome: Systemic eosinophilic conditions, such as Churg-Strauss syndrome, may occur when using ArmonAir Digihaler or AirDuo Digihaler. Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy
  • Coexisting Conditions: Use AirDuo Digihaler with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines
  • Hypokalemia and Hyperglycemia: Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. Decrease in serum potassium are usually transient, not requiring supplementation. Be alert to hypokalemia and hyperglycemia in patients using AirDuo Digihaler
  • Adverse Reactions with ArmonAir Digihaler: Most common adverse reactions (greater than or equal to 3%) are: upper respiratory tract infection, nasopharyngitis, oral candidiasis, headache, and cough
  • Adverse Reactions with AirDuo Digihaler: Most common adverse reactions (greater than or equal to 3%) include nasopharyngitis, oral candidiasis, headache, cough and back pain

INDICATIONS FOR AIRDUO AND ARMONAIR DIGIHALER

ArmonAir Digihaler inhalation powder is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.

Limitation of Use: ArmonAir Digihaler is not indicated for the relief of acute bronchospasm.

AirDuo Digihaler inhalation powder is indicated for the treatment of asthma in patients 12 years of age and older. AirDuo Digihaler is only for patients uncontrolled on an inhaled corticosteroid (ICS) or whose disease severity clearly warrants an ICS/Long-acting beta2-agonist (LABA).

Limitation of Use: AirDuo Digihaler is not indicated for the relief of acute bronchospasm.

ArmonAir Digihaler and AirDuo Digihaler contain a built-in electronic module which detects, records, and stores data on inhaler events for transmission to mobile App. Use of the App is not required for administration of medication to the patient.

Please see full Prescribing Information for ArmonAir Digihaler and AirDuo Digihaler.

Important Safety Information:

PROAIR® DIGIHALER® (albuterol sulfate)

  • Contraindications: ProAir Digihaler Inhalation Powder is contraindicated in patients with hypersensitivity to albuterol or patients with a severe hypersensitivity to milk proteins. Rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. There have been reports of anaphylactic reactions in patients using inhalation therapies containing lactose
  • Paradoxical Bronchospasm: ProAir Digihaler can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir Digihaler and institute alternative therapy if paradoxical bronchospasm occurs
  • Deterioration of Asthma: Need for more doses of ProAir Digihaler than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids
  • Use of Anti-Inflammatory Agents: ProAir Digihaler alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids
  • Cardiovascular Effects: ProAir Digihaler, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
  • Do Not Exceed Recommended Dose: Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma
  • Hypersensitivity Reactions including Anaphylaxis: Immediate hypersensitivity reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Hypersensitivity reactions including anaphylaxis, angioedema, pruritus, and rash have been reported with the use of therapies containing lactose, an inactive ingredient in ProAir Digihaler.
  • Coexisting Conditions: ProAir Digihaler, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.
  • Hypokalemia: As with other beta-agonists, ProAir Digihaler may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation
  • Most common adverse reactions (≥1% and >placebo) are back pain, pain, gastroenteritis viral, sinus headache, urinary tract infection, nasopharyngitis, oropharyngeal pain and vomiting
  • Drug Interactions: Other short-acting sympathomimetic bronchodilators should not be used concomitantly with ProAir Digihaler
    • Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir Digihaler, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers
    • Diuretics: Caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels
    • Digoxin: Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir Digihaler
    • Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir Digihaler should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy

INDICATION FOR PROAIR DIGIHALER

ProAir Digihaler Inhalation Powder is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and in patients 4 years of age and older for the prevention of exercise-induced bronchospasm.

ProAir Digihaler contains a built-in electronic module that detects, records and stores inhaler event information. ProAir Digihaler may be used with, and transmits information to, a mobile app. Use of the mobile app is not required for administration of medication to the patient.

Please see full Prescribing Information for ProAir Digihaler.

Devices comply with part 15 of the FCC Rules. Operation is subject to the following two conditions: (1) These devices may not cause harmful interference, and (2) these devices must accept any interference received, including interference that may cause undesired operation. Changes or modifications not expressly approved by Teva could void the user's authority to operate the equipment.

References: 1. ProAir Digihaler. Prescribing Information. Teva; 2022. Accessed July 1, 2022. https://www.digihalerhcp.com/globalassets/
proair_digihaler/
proair_digihaler_pi.pdf 2. AirDuo Digihaler. Prescribing information. Teva; 2022. Accessed July 1, 2022. https://
www.digihalerhcp.com/globalassets/
airduo_digihaler/airduo_digihaler_pi.pdf 3. ArmonAir Digihaler. Prescribing Information. Teva; 2022. Accessed July 1, 2022. https://
www.digihalerhcp.com/
globalassets/
armonair_digihaler/armonair_digihaler_pi.pdf 4. Sulaiman I, Seheult J, MacHale E, et al. Irregular and ineffective: a quantitative observational study of the time and technique of inhaler use. J Allergy Clin Immunol Pract. 2016;4(5):900-909. 5. Patel M, Perrin K, Pritchard A, et al. Accuracy of patient self-report as a measure of inhaled asthma medication use. Respirology. 2013;18(3):546-552. 6. Unni E, Gabriel S, Ariely R. A review of the use and effectiveness of digital health technologies in patients with asthma. Ann Allergy Asthma Immunol. 2018;121(6):680-691. 7. Silver HS, Blanchette CM, Kamble S, et al. Quarterly assessment of short-acting beta(2)-adrenergic agonist use as a predictor of subsequent health care use for asthmatic patients in the United States. J Asthma. 2010;47(6):660-666. 8. Azzi EA, Kritikos V, Peters MJ, et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey. BMJ Open. 2019;9(8):e028995. 9. Hoyte FCL, Mosnaim GS, Rogers L, et al. Effectiveness of a digital inhaler system for patients with asthma: a 12-week, open-label, randomized study (CONNECT1). J Allergy Clin Immunol Pract. 2022;10(10):2579-2587. 10. Advair Diskus Prescribing Information. GSK; 2020. Accessed September 13 2022. https://gskpro.com/
content/dam/global/hcpportal/en_US/
Prescribing_Information/
Advair_Diskus/pdf/
ADVAIR-DISKUS-PI-PIL-IFU.PDF 11. Flovent HFA Prescribing Information. GSK; 2022. Accessed September 13, 2022. https://gskpro.com/
content/
dam/global/hcpportal/en_US/
Prescribing_Information/Flovent_HFA/pdf/
FLOVENT-HFA-PI-PIL-IFU.PDF 12. Flovent Diskus Prescribing Information. GSK; 2022. Accessed September 13, 2022. https://gskpro.com/
content/dam/global/hcpportal/en_US/
Prescribing_Information/Flovent_Diskus/pdf/
FLOVENT-DISKUS-PI-
PIL-IFU.PDF 13. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930-938. 14. Data on File. Frazer, PA: Teva Respiratory, LLC. 15. Brooke J. SUS: a “quick and dirty” usability scale. In Jordan PW, Thomas B, Weerdmeester BA, McClelland IL, eds. Usability Evaluation in Industry. Taylor & Francis Ltd; 1996:189-194.

​ ​

You are about to leave this site.

You are about to leave DigihalerHCP.com and enter a website operated by a third party.

Would you like to continue?

Yes
​ ​

Due to technical changes in Google policies, the Digihaler app was temporarily removed from the Google Play Store.

We are working on an update and will publish a new version soon. If you would like more information or a notification when the app is available again, please call our team at 888-603-0788.

Note: This does not affect the Apple App Store.

​ ​

This site is intended for US
healthcare professionals

I am a patient or caregiver